

GERM™



ETFMG Treatments, Testing and Advancements ETF

as of 3/31/23

GERM™ is designed to give exposure to the biotech companies engaged in the testing and treatments of infectious diseases. Focused on advancements with targeted exposure to the forefront of R&D, vaccines, therapies and testing technologies.



Healthcare advancements have had the most impact in combating different diseases, with vaccines, therapies and testing being at the forefront of those developments.



There are over 20 combined epidemic and pandemic-prone diseases affecting the world today.⁴



Global biotechnology services market is expected to grow from \$146.85 billion in 2022 to \$163.71 billion in 2023 at a CAGR of 11.5%.⁵



Variations of coronavirus have been medically documented in approx. 9 instances since 1965.⁶


Performance

	CUMULATIVE				ANNUALIZED					
	1 MONTH	3 MONTH	YTD	SINCE INCEP.	1 YEAR	3 YEARS	5 YEARS	10 YEARS	SINCE INCEP.	
MARKET PRICE	-2.76%	-8.26%	-8.26%	-16.42%	-24.49%					-6.23%
NAV	-3.10%	-8.56%	-8.56%	-14.07%	-22.26%					-5.30%
INDEX	-2.98%	-8.97%	-8.97%	-15.16%	-22.74%					-5.73%


Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance of the Funds may be lower or higher than the performance quoted. All performance is historical and includes reinvestment of dividends and capital gains. Performance data current to the most recent month end may be obtained by calling 1-844-ETF-MGRS (1-844-383-6477). Performance is annualized for periods greater than 1 year.

Prime Classification Weighting Distribution

As of 12/31/22



Country Exposure (%)



FOR MORE INFORMATION

Website: etfmfg.com/GERM
 Email: info@etfmfg.com
 Sales Inquiries: 1.844.ETF.MGRS

FUND INFORMATION

Fund Inception 6/17/20
 Ticker GERM
 AUM¹ \$18.9M
 CUSIP 26924G763
 ISIN US26924G7631
 Stock Exchange NYSE ARCA
 Expense Ratio 0.68%
 Security Lending Income³ 0.63%
 Intraday NAV (IIV) GERM.IV
 NAV Symbol GERM.NV
 Rebalance Freq. Quarterly

TOP 10 FUND HOLDINGS (%)

Moderna Inc 6.70
 Alnylam Pharmaceuticals Inc 6.29
 Quest Diagnostics Inc 6.25
 Biontech SE 6.00
 Lab Corp of America Holdings 5.88
 Vir Biotechnology Inc 4.25
 Quidelortho Corp 4.17
 Bio Rad Labs Inc 3.92
 Zai Lab Ltd 3.82
 Immunocore Holdings Plc 3.81

KEY INDEX FACTS

Index Provider Prime Indexes
 No. of Holdings² 66
 Index Ticker PGERMN

etfmfg.com/GERM

This fund is a series in the ETF Managers Trust

About the Fund

The ETFMG Treatments, Testing and Advancements ETF (GERM™) holds U.S.-listed companies engaged in and at the forefront of R&D, vaccines, therapies and testing technologies.

The Fund's investment objective seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the Prime Treatments, Testing and Advancements Index.

Did You Know?

The frequency and diversity of disease outbreaks have grown steadily for the past 30 years. Growth in travel, trade and connectivity are key factors.*

The global vaccines market is one of the fastest-growing biotech segments.**

About the Index

The Prime Treatments, Testing and Advancements Index (the "Index") is an Index of Prime Indexes, a division of Level ETF Ventures LLC. The Index has been created to provide investors with a reference measure that enables them to track both event-driven news and long-term trends of companies engaged in developing treatments and vaccines, or diagnostic technology, in the fight against infectious diseases.

The Index is designed to include the securities of companies engaged in performing research, development and commercialization of treatments, vaccines or biological testing for infectious diseases. These companies are known collectively as "Treatments, Testing and Advancement Companies." An investment cannot be made directly in an Index.

Carefully consider the Fund's investment objectives, risk factors, charges, and expenses before investing. This and additional information can be found in the Fund's prospectus, which may be obtained by calling 1-844-ETF-MGRS (1-844-383-6477), or by visiting www.etfmg.com/GERM. Read the prospectus carefully before investing.

¹ AUM as of 3/31/23 and is subject to change on a daily basis.

² Holdings are subject to change without notice.

³ Security Lending income is expressed as the result of dividing net securities lending income for the twelve months ending 3/31/23 divided by the average daily net assets of the Fund for the same period.

⁴ Source: www.emro.who.int

⁵ Source: www.thebusinessresearchcompany.com

⁶ Source: www.the-scientist.com

Investing involves risk, including loss of principal. Shares of any ETF are bought and sold at market price (not NAV), may trade at a discount or premium to NAV and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Narrowly focused investments typically exhibit higher volatility. Treatment Companies and Testing Companies are involved in discovering, developing and commercializing novel drugs or tests with significant market potential. These companies face challenges including pre-clinical testing and clinical trial stages of development. Clinical trials may be delayed and certain programs may never advance in the clinic or may be more costly to conduct than anticipated. Such companies may be dependent on their ability to secure significant funding for research, development, and commercialization of therapeutics, vaccines, tests, and other health care products or services. If there are delays in obtaining required regulatory and marketing approvals for products, the ability of such companies to generate revenue may be materially impaired. If regulatory approval is obtained, products will still remain subject to regulatory scrutiny with regulatory authorities having the ability to impose significant restrictions on the indicated uses or marketing. Lastly, even if a licensed product is achieved, such companies may encounter difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management, or shipping.

ETF Managers Group LLC is the investment adviser to the Fund.

The Fund is distributed by ETFMG Financial LLC. ETF Managers Group LLC and ETFMG Financial LLC are wholly owned subsidiaries of Exchange Traded Managers Group LLC (collectively, "ETFMG"). ETFMG is not affiliated with Prime Indexes.

The Fund is intended to be made available only to U.S. residents. Under no circumstances is any information provided on this website intended for distribution to or use by, or to be an offer to sell to or solicitation of an offer to buy the Fund or any investment product or service of, any person or entity in any jurisdiction or country, other than the United States, where such distribution, use, offer or solicitation would subject the Fund or its affiliates to any registration requirement or be unlawful under the securities laws of that jurisdiction or country.

*World Economic Forum white paper, "Outbreak Readiness and Business Impact Protecting Lives and Livelihoods across the Global Economy", in collaboration with Harvard Global Health Institute, Jan. 2019. Source: weforum.org

**Vaccines and Vaccination conference series, Transparency Market Research, June 2020, Market analysis: europe.vaccineconferences.com